An interventional study of Free gingival graft and Free Gingival Graft with i-PRF in Lack of Keratinized Tissue, Mucogingival Surgery and Gingival Recession, sponsored by Saglik Bilimleri Universitesi. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Treatment
Among 69 studies in Gingival Recession with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Gingival Recession · Turkey.
Among the 69 studies in Gingival Recession with a site in Turkey, this one is the 15th largest by planned enrollment of the 56 interventional ones, is one of 5 that started in 2026, is one of 52 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 69th registered.
426 studies on the registry are indexed under Gingival Recession; 106 are open to participants now.
This study's planned enrollment of 45 is above the median of 30 across 390 interventional studies indexed under Gingival Recession.
Browse Gingival Recession studies →14 of the 69 studies in Gingival Recession with a site in Turkey are open now, in 1 country. Each count lists the studies.
Of the 64 Gingival Recession studies recruiting now, 30 (47%) set no upper age limit and 31 (48%) stop at 75 or younger; 1 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →69 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2026.
Median enrollment 36 across the 56 interventional studies, 80 across the 13 observational. Of the 52 that completed or were terminated, 0 (0%) have results posted.
None of the 69 has an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi is the lead sponsor of 453 studies on the registry; 140 are open to participants now.
Saglik Bilimleri Universitesi has 2 studies filed under Gingival Recession — fewer than ten, so there is no comparison to draw.
4 of the studies in Gingival Recession with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07804888Saglik Bilimleri UniversitesiEvaluation of the Effects of Injectable Platelet-Rich Fibrin and Hyaluronic Acid Treatments, Administered in Addition to Free Gingival Graft Therapy, on Clinical Healing. | 2027-01 |
| NCT07777185Ankara UniversityEvaluation of the Effect of Smoking on Palatal Donor Site Tissue Profile in the Success of Connective Tissue Grafts | 2027-02-20 |
| NCT07349056Trakya UniversityEarly Effects of Orthognathic Surgery on Periodontal Phenotype: A 6-Month Prospective Clinical and Radiographic Evaluation | 2027-02-23 |
| NCT07751211Altinbas UniversityEffects of Low-Level Laser Therapy and Hyaluronic Acid After Free Gingival Graft | 2027-03-06 |
Among the 69 studies in Gingival Recession with a site in Turkey, from their registry updates:
The purpose of this clinical trial is to evaluate the effects of injectable platelet-rich fibrin (i-PRF) and hyaluronic acid (HA) gel on clinical healing and graft shrinkage when used in addition to Free Gingival Graft (FGG) surgery. The study involves patients with gingival recession and insufficient keratinized tissue. Participants will be randomly divided into three groups: FGG with i-PRF application, FGG with HA gel application, Conventional FGG alone (Control group). The main goal is to compare the amount of graft shrinkage and evaluate clinical wound healing parameters between these groups over a 3-month follow-up period.
Gingival recession and inadequate keratinized tissue are common mucogingival problems that can compromise periodontal health. Free gingival graft (FGG) therapy is considered the gold standard for increasing keratinized tissue; however, dimensional shrinkage of the graft during the healing process remains a significant clinical challenge. The survival and success of the graft depend heavily on rapid revascularization.
This randomized controlled clinical trial aims to investigate whether the adjunctive use of biological agents can minimize graft shrinkage and enhance soft tissue healing.
All eligible patients will initially receive non-surgical Phase 1 periodontal therapy, including professional plaque removal and oral hygiene instructions.
During the surgical phase, a partial-thickness recipient bed will be prepared in the mandibular incisor region. A free gingival graft of approximately 1 to 1.5 mm thickness will be harvested from the palatal donor site.
Depending on the randomization assignment:
In the first experimental group, the harvested FGG will be hydrated in injectable platelet-rich fibrin (i-PRF), which is obtained from the patient's own venous blood via centrifugation, prior to being sutured to the recipient bed.
In the second experimental group, the FGG will be hydrated in a 0.8% hyaluronic acid (HA) gel before fixation.
In the control group, the FGG will be applied and sutured conventionally without the use of any additional biological agents.
Following graft fixation, a periodontal dressing will be applied to protect the recipient site, and a custom surgical stent combined with a hemostatic sponge will be used to stabilize the palatal donor site. Patients will be prescribed postoperative medications (antibiotics, analgesics, and antibacterial mouthwash) and advised on a soft diet. Standardized clinical photographs and digital image analysis software will be utilized to accurately measure graft dimensional changes during the follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Free gingival graft combined with injectable platelet-rich fibrin (i-PRF).
Procedure: Free Gingival Graft with i-PRF
Free gingival graft combined with 0.8% hyaluronic acid gel.
Procedure: Free Gingival Graft with Hyaluronic Acid
Conventional free gingival graft applied without any additional biological agents.
Procedure: Free gingival graft
The free gingival graft is obtained from the palatal donor site (1-1.5 mm thickness) and directly applied and sutured to the recipient site without any additional biological agents.
Also known as: Conventional FGG
The free gingival graft is obtained from the palatal donor site (1-1.5 mm thickness) and hydrated in injectable platelet-rich fibrin (i-PRF) before fixation at the recipient site. i-PRF is prepared by centrifuging the patient's venous blood at 2500 rpm for 3 minutes.
Also known as: FGG + injectable platelet-rich fibrin
The free gingival graft is obtained from the palatal donor site (1-1.5 mm thickness) and soaked in 0.8% hyaluronic acid (HA) gel before fixation at the recipient site.
Also known as: FGG with 0.8% HA gel, Gingigel
Percentage of Graft Shrinkage
Graft shrinkage will be evaluated by calculating the surface area of the graft in square millimeters using standardized clinical photographs and ImageJ software. The percentage of shrinkage is calculated with the formula: ((Immediate post-operative graft area - Follow-up graft area ) / Immediate post-operative graft area) x 100.
Time frame: Baseline, 1 month, and 3 months post-operation
Probing Depth (PD)
Measurement of Probing Depth (PD) in millimeters using a UNC-15 periodontal probe.
Time frame: Baseline, 1 month, and 3 months post-operation
Wound Healing Index
Soft tissue healing will be assessed using the Landry, Turnbull, and Howley Index. Scores range from 1 (very poor) to 5 (excellent) based on parameters such as tissue color, bleeding on palpation, presence of granulation tissue, and incision margins.
Time frame: 7 days, 14 days, 21 days, 1 month, and 3 months post-operation
Root Coverage Esthetic Score (RES)
Objective evaluation of the esthetic outcomes using the Root Coverage Esthetic Score (RES). The system evaluates five anatomical variables (gingival margin, marginal tissue contour, soft tissue texture, mucogingival junction alignment, and gingival color). The total score ranges from 0 to 10, with 10 representing a perfect esthetic outcome. Gingival Margin (GM): Scored as 0, 3, or 6 points depending on the amount of root coverage. Marginal Tissue Contour (MTC): 1 point if regular/proper, 0 points if irregular. Soft Tissue Texture (STT): 1 point if harmonious with the adjacent tissue, 0 points if not. Mucogingival Junction Alignment (MGJ): 1 point if aligned with the adjacent MGJ, 0 points if not. Gingival Color (GC): 1 point if there is a color match with the adjacent tissue, 0 points if not. The total score ranges from a minimum of 0 to a maximum of 10, where higher scores mean a better esthetic outcome.
Time frame: 3 months post-operation
Clinical Attachment Level (CAL)
Measurement of clinical attachment level in millimeters using a UNC-15 periodontal probe.
Time frame: Baseline, 1 month, and 3 months post-operation
Gingival Recession Height
Measurement of gingival recession height in millimeters using a UNC-15 periodontal probe.
Time frame: Baseline, 1 month, and 3 months post-operation.
Keratinized Tissue Height
Measurement of keratinized tissue height in millimeters using a UNC-15 periodontal probe.
Time frame: Baseline, 1 month, and 3 months post-operation.
Keratinized Tissue Thickness
Keratinized tissue thickness was measured using a size 25 endodontic spreader equipped with a silicone stopper. Following tissue penetration, the distance from the tip of the spreader to the stopper was measured using a digital electronic caliper in millimeters.
Time frame: Baseline and 3 months post-operation.
Postoperative Pain
Postoperative pain intensity will be evaluated daily by the patients using a 10 cm Visual Analogue Scale (VAS), where 0 indicates no pain and 10 indicates the worst imaginable pain.
Time frame: Up to 7 days post-operation
Patient-Reported Comfort Level: Postoperative Bleeding
Patient-reported comfort levels regarding postoperative bleeding will be assessed daily using a 5-point Likert scale. The scale ranges from 1 to 5 (1 = Very dissatisfied, 5 = Very satisfied), where higher scores indicate greater aesthetic satisfaction. minimum 1 to a maximum of 5, where higher scores mean a better outcome.
Time frame: Up to 14 days post-operation
Patient-Reported Comfort Level: Postoperative Edema
Patient-reported comfort levels regarding postoperative edema will be assessed daily using a 5-point Likert scale. The scale ranges from 1 to 5 (1 = Very dissatisfied, 5 = Very satisfied), where higher scores indicate greater aesthetic satisfaction. minimum 1 to a maximum of 5, where higher scores mean a better outcome.
Time frame: Up to 14 days post-operation
Patient-Reported Comfort Level: Difficulty Speaking
Patient-reported comfort level regarding difficulty speaking will be assessed daily using a 5-point Likert scale. The score ranges from a minimum of 1 to a maximum of 5 (1 = Very dissatisfied/Severe discomfort, 5 = Very satisfied/No discomfort), where higher scores mean a better outcome (greater patient comfort).
Time frame: Up to 14 days post-operation
Patient-Reported Comfort Level: Difficulty Eating
Patient-reported comfort level regarding difficulty eating will be assessed daily using a 5-point Likert scale. The score ranges from a minimum of 1 to a maximum of 5 (1 = Very dissatisfied/Severe discomfort, 5 = Very satisfied/No discomfort), where higher scores mean a better outcome (greater patient comfort). minimum 1 to a maximum of 5, where higher scores mean a better outcome
Time frame: Up to 14 days post-operation
Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in the published article will be shared. This includes the primary and secondary outcome measures (clinical periodontal parameters, graft shrinkage data, wound healing index scores, Root Coverage Esthetic Scores, and patient comfort data). Patient identities and any identifying information will remain strictly confidential and will not be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will become available beginning 3 months following article publication and will be accessible for up to 3 years.
Access criteria: Data will be shared with researchers who provide a methodologically sound proposal to achieve the specific aims outlined in the approved proposal. Requests should be directed to the principal investigator via email. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.
Of 233 non-industry interventional studies with no phase under Gingival Recession, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 4 months is below that.
Counting every sponsor, half of 235 studies reached it within 19 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →